Kerala Ayurveda Ltd

Kerala Ayurveda Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 February 2026, providing investors with the latest insights into the stock’s performance and outlook.

Kerala Ayurveda Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.230.1 today, marking a significant decline amid a sustained downward trend. The stock’s performance continues to lag behind sector peers and broader market indices, reflecting ongoing pressures on the company’s financial metrics and market sentiment.

Kerala Ayurveda Ltd’s shares declined sharply to a fresh 52-week low of Rs.240.1 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent financial headwinds and subdued operational metrics.

Kerala Ayurveda Ltd’s shares declined to a fresh 52-week low of Rs.260.75 on 27 Jan 2026, marking a significant downturn for the pharmaceutical and biotechnology company. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued operational performance.

Kerala Ayurveda Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Kerala Ayurveda Ltd’s shares declined sharply to a fresh 52-week low of Rs.265.1 on 21 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed both its sector and the broader market, reflecting a series of financial and market pressures that have weighed on investor sentiment.

Kerala Ayurveda Ltd’s shares declined to a fresh 52-week low of Rs.281.25 on 20 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed both its sector and the broader market over the past year, reflecting persistent financial pressures and subdued growth metrics.

Kerala Ayurveda Ltd’s shares declined to a fresh 52-week low of Rs.290.1 on 19 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has been under pressure, reflecting a series of financial and market challenges that have weighed on investor sentiment.

Kerala Ayurveda Ltd’s shares declined sharply to a new 52-week low of Rs.290.5 on 14 Jan 2026, reflecting ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Kerala Ayurveda Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Kerala Ayurveda Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Kerala Ayurveda, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and operational challenges. This shift in assessment highlights concerns across multiple analytical parameters, including quality, valuation, financial trends, and technical outlook, underscoring the company’s current market position and investor sentiment.

Kerala Ayurveda’s shares reached a fresh 52-week low of Rs.301.35 today, marking a significant decline amid ongoing financial pressures and subdued market performance. The stock has been under pressure for the past two sessions, reflecting challenges in the company’s financial health and market sentiment.

Kerala Ayurveda, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting shifts in its financial health and technical outlook. This adjustment highlights ongoing challenges in the company’s fundamentals and market positioning, prompting investors to reassess its prospects amid sector dynamics.

Kerala Ayurveda, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory.

Kerala Ayurveda Ltd., a micro-cap pharmaceutical company specialising in Ayurvedic products and wellness services, reported a consolidated net loss of ₹6.34 crores for Q2 FY26, a sharp deterioration from a profit of ₹1.99 crores in Q1 FY26. The quarter-on-quarter decline of 418.59% and year-on-year plunge of 285.38% underscore mounting operational pressures that have eroded profitability despite modest revenue growth. The company's market capitalisation stands at ₹470.00 crores, with shares trading at ₹385.00 as of November 18, 2025.